- Home
- CHRS vs CSTE Comparison
CHRS vs CSTE Comparison
Compare CHRS & CSTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- CSTE
- Stock Information
- Founded
- CHRS 2010
- CSTE 1987
- Country
- CHRS United States
- CSTE Israel
- Employees
- CHRS N/A
- CSTE N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- CSTE Building Materials
- Sector
- CHRS Health Care
- CSTE Industrials
- Exchange
- CHRS Nasdaq
- CSTE Nasdaq
- Market Cap
- CHRS 112.5M
- CSTE 105.4M
- IPO Year
- CHRS 2014
- CSTE 2012
- Fundamental
- Price
- CHRS $0.78
- CSTE $1.70
- Analyst Decision
- CHRS Buy
- CSTE Strong Buy
- Analyst Count
- CHRS 3
- CSTE 1
- Target Price
- CHRS $4.68
- CSTE $6.00
- AVG Volume (30 Days)
- CHRS 1.5M
- CSTE 153.3K
- Earning Date
- CHRS 05-12-2025
- CSTE 05-07-2025
- Dividend Yield
- CHRS N/A
- CSTE N/A
- EPS Growth
- CHRS N/A
- CSTE N/A
- EPS
- CHRS N/A
- CSTE N/A
- Revenue
- CHRS $272,251,000.00
- CSTE $424,487,000.00
- Revenue This Year
- CHRS N/A
- CSTE N/A
- Revenue Next Year
- CHRS $19.78
- CSTE $6.60
- P/E Ratio
- CHRS $1.83
- CSTE N/A
- Revenue Growth
- CHRS 19.87
- CSTE N/A
- 52 Week Low
- CHRS $0.66
- CSTE $1.67
- 52 Week High
- CHRS $2.43
- CSTE $6.54
- Technical
- Relative Strength Index (RSI)
- CHRS 40.90
- CSTE 22.55
- Support Level
- CHRS $0.74
- CSTE $1.72
- Resistance Level
- CHRS $0.82
- CSTE $1.93
- Average True Range (ATR)
- CHRS 0.07
- CSTE 0.13
- MACD
- CHRS -0.00
- CSTE -0.01
- Stochastic Oscillator
- CHRS 19.71
- CSTE 5.17
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About CSTE Caesarstone Ltd.
Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa).